

# miR-194通过靶定DNMT3A基因调控肝癌细胞的生长

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年02期 页码: 187-192 栏目: 论著(基础研究) 出版日期: 2018-12-08

**Title:** Regulation of miR-194 on growth of hepatocellular carcinoma cell through targeting DNMT3A

**作者:** 马一栋<sup>1</sup>; 杨茜<sup>1</sup>; 霍月红<sup>2</sup>; 尉继林<sup>3</sup>; 丁志明<sup>3</sup>; 席海英<sup>4</sup>  
1.大同市第五人民医院肿瘤科; 2.风湿免疫科; 3.检验科; 4.皮肤科, 山西 大同 037009

**Author(s):** Ma Yidong<sup>1</sup>; Yang Qian<sup>1</sup>; Huo Yuehong<sup>2</sup>; Yu Jilin<sup>3</sup>; Ding Zhiming<sup>3</sup>; Xi Haiying<sup>4</sup>  
1.Department of Oncology;2.Department of Rheumatology and Immunology;3.Department of Clinical Laboratory;4.Department of Dermatology,The Fifth People's Hospital of Datong,Shanxi Datong 037009,China.

**关键词:** 微小RNA-194; HepG2细胞; 增殖; 细胞周期; 甲基化转移酶3A

**Keywords:** miR-194; HepG2; proliferation; cell cycle; DNMT3A

**分类号:** R735.7

**DOI:** 10.3969/j.issn.1672-4992.2019.02.002

**文献标识码:** A

**摘要:** 目的:探讨miR-194对肝癌细胞增殖和细胞周期的影响及其潜在的作用机制。方法:实时定量聚合酶链式反应检测肝癌细胞系HepG2和正常肝细胞系L-O2中miR-194的表达水平。构建miR-194过表达质粒,采用MTT法检测细胞增殖活力,流式细胞术检测细胞周期;双荧光素酶报告基因分析法预测和验证miR-194可能的靶基因。结果:实时定量PCR结果显示,miR-194在肝癌细胞中的表达明显低于肝脏正常细胞。在肝癌细胞中过表达miR-194抑制细胞生长。而流式细胞术检测发现细胞周期进程减慢,G1期比例增加,S期比例相应的减少。靶基因筛选得到DNMT3A为miR-194的候选靶基因。荧光报告载体实验证实,miR-194能够通过作用于靶基因3'非翻译区的特定位点,对其表达在转录后进行负性调节。而在miR-194表达增加的肝癌细胞中,靶基因的mRNA表达水平和蛋白表达水平都有明显降低。在肝癌细胞HepG2中,敲除靶基因DNMT3A后,细胞的增殖能力减弱,相反,当把DNMT3A过表达后,细胞的增殖能力增强,可以挽救miR-194对细胞的表型影响。结论:miR-194可通过靶定DNMT3A基因抑制肝癌细胞的生长。

**Abstract:** Objective:To explore effect of miR-194 on proliferation and cell cycle of the human hepatocellular carcinoma cell and its potential mechanism.Methods:Expressions of miR-194 in hepatoma cell line HepG2 as well as normal liver cell L-O2 were detected by RT-PCR.The plasmid with over-expression of miR-194 was constructed.MTT and FACS were respectively used to measure proliferation ability of the cells and cell cycle.Possible target gene of miR-194 was forecasted and verified with dual luciferase report gene assay.Results:Compared with normal liver cell,miR-194 is low-expressed in HepG2.Over-expression of miR-194 decreased cell growth.FACS showed miR-194 arrested cells cycle in G1 phase.The DNMT3A was identified to be a putative target gene,whose mRNA 3'-untranslated region (3' UTR) contains the potential binding site of miR-194.The fluorescent reporter experiment also confirmed that miR-194 can directly bind to the target genes mRNA 3' UTR.The mRNA and protein level of DNMT3A in HepG2 gave the clue that miR-194 can negatively regulate the genes expression through mRNA decay.Knockdown of DNMT3A by RNA interference can decrease the cell proliferation.Finally,when cells were transfected with DNMT3A and miR-194,the cell proliferation ability was significantly recovered comparing to the cells transfected with pcDNA and miR-194.Conclusion:miR-194 could inhibit proliferation and cell cycle of the hepatocellular carcinoma cell through targeting DNMT3A.

## 参考文献/REFERENCES

- [1] Bosch FX,Ribes J,Diaz M,et al.Primary liver cancer:Worldwide incidence and trends [J] .Gastroenterology,2004,127(5 Suppl 1):S5-S16.
- [2] Di Bisceglie AM.Issues in screening and surveillance for hepatocellular carcinoma [J] .Gastroenterology,2004,127(5 Suppl 1):S104-107.
- [3] Luo Q,Li Y,Deng J,et al.PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via

- abrogation of G2/M checkpoint and suppression of DNA damage repair [J]. *Chem Biol Interact*,2015,226:12-22.
- [4] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function [J]. *Cell*,2004,116(2):281-297.
- [5] Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets [J]. *Proc Natl Acad Sci USA*,2006,103(7):2257-2261.
- [6] Liese J, Peveling-Oberhag J, Doering C, et al. A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation [J]. *Transpl Int*,2016,29(3):369-380.
- [7] Tuna M, Machado AS, Calin GA. Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases [J]. *Genes Chromosomes Cancer*,2016,55(3):193-214.
- [8] Tanaka Y, Kozu T. miRNA in disease and therapeutic development [J]. *Tanpakushitsu Kakusan Koso*,2006,51(16 Suppl):2509-2514.
- [9] Zhou L, Di Q, Sun B, et al. MicroRNA-194 restrains the cell progression of non-small cell lung cancer by targeting human nuclear distribution protein C [J]. *Oncol Rep*,2016,35(6):3435-3444.
- [10] An J, Lv W, Zhang Y. LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194 [J]. *Onco Targets Ther*,2017,10:5377-5390.
- [11] Chang HY, Ye SP, Pan SL, et al. Overexpression of miR-194 reverses HMG2A-driven signatures in colorectal cancer [J]. *Theranostics*,2017,7(16):3889-3900.
- [12] Cai HK, Chen X, Tang YH, et al. MicroRNA-194 modulates epithelial-mesenchymal transition in human colorectal cancer metastasis [J]. *Onco Targets Ther*,2017,10:1269-1278.
- [13] Li P, Yang Y, Liu H, et al. MiR-194 functions as a tumor suppressor in laryngeal squamous cell carcinoma by targeting Wee1 [J]. *J Hematol Oncol*,2017,10(1):32.
- [14] Bao J, Zou JH, Li CY, et al. miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B [J]. *Eur Rev Med Pharmacol Sci*,2016,20(21):4487-4493.
- [15] Di Croce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor [J]. *Science*,2002,295(5557):1079-1082.
- [16] Li H, Rauch T, Chen ZX, et al. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells [J]. *J Biol Chem*,2006,281(28):19489-19500.
- [17] Tovy A, Spiro A, McCarthy R, et al. p53 is essential for DNA methylation homeostasis in naive embryonic stem cells, and its loss promotes clonal heterogeneity [J]. *Genes Dev*,2017,31(10):959-972.
- [18] Majumder S, Ghoshal K, Datta J, et al. Role of DNA methyltransferases in regulation of human ribosomal RNA gene transcription [J]. *J Biol Chem*,2006,281(31):22062-22072.
- [19] Scardocci A, Guidi F, D'Alo' F, et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia [J]. *Br J Cancer*,2006,95(8):1108-1113.
- [20] Gong C, Fujino K, Monteiro LJ, et al. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer [J]. *Oncogene*,2015,34(39):5012-5024.

---

**备注/Memo:** 大同市基础 Research 计划项目 (编号: 2015103)

---

更新日期/Last Update: 1900-01-01